Viridian Therapeutics (VRDN) Announces Proposed $150M Share and Warrant Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall St dips after AI-led selloff; SpaceX worries hit telecoms
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude hits more than five-month high on Houthi-Saudi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
- AMD shares fall amid AI chip sector selloff
- JetBlue shares fall amid American results, fuel cost concerns
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Nokia shares fall despite earnings beat on cash flow concerns
Viridian Therapeutic (VRDN) PT Raised to $31 at Goldman Sachs
September 12, 2024 5:07 AM EDTGoldman Sachs analyst Richard Law raised the price target on Viridian Therapeutic (NASDAQ: VRDN) to $31.00 (from $25.00) while maintaining a Buy rating.
The analyst comments "We update our model to reflect increased POS for veligrotug (VRDN-001) following positive topline results from the Ph. 3 THRIVE... More



